Welcome to the BSG Global Grand Rounds, brought to you by the International Section of the BSG. This webinar series aims to cover the SCE curriculum with speakers from across the globe giving us an international perspective on common gastro- intestinal conditions.

Learning points

• NAFLD is the leading cause of liver disease and increasingly liver cancer 
• Early identification of those at risk can prevent the progression to cirrhosis 
• Lifestyle modification is the cornerstone of management

About our speakers

Prof Ian Cua, Head, Institute of Digestive & Liver Diseases, St Luke’s Medical Centre, Manila

Second Vice President, Philippine Society of Gastroenterology

• Head, Institute of Digestive and Liver Diseases  St. Luke’s Medical Center, Global City, Philippines
• Chief, Section of Hepatology, Institute of Digestive and Liver Diseases, St. Luke’s Medical Center, Quezon City, Philippines
• Member, Hepatology Interest Group, World Gastroenterology Organization
• Past President, Hepatology Society of the Philippines

Dr Michael Alison, Consultant Hepatologist, Cambridge University Hospitals NHS Foundation Trust

Dr Michael Allison is a consultant hepatologist at Cambridge Universities Hospitals NHS Foundation Trust. He is a member of the EPoS consortium awarded an H2020 EU grant to investigate mechanisms of NASH and a grant-holder for translational research into the inter-relationship between liver fat and insulin resistance in collaboration with Professor Toni Vidal-Puig in the Institute of Metabolic Science (IMS) and also the MRC Human Nutrition Research Unit, linking human work with in vitro and animal model work in the IMS. He is also a Co-Applicant on the LITMUS IMI application for EU funding. He is a member of NAFLD-UK and Principle Investigator for a number of Clinical Research Network supported Phase 2 and Phase 3 Clinical Trials in NASH and alcoholic hepatitis and works closely with the CRN Research Nurse team to conduct these studies as well as using the Wellcome Trust Clinical Research Facility on-site. Having been a coapplicant on the HTA-funded STOPAH Trial in severe alcoholic hepatitis as well as a member of the Trial Steering Group, he is collaborating with the MRC Biostatistics Unit on-site to develop novel predictive tools for outcome and treatment options in this condition and developing the next multicentre study in severe alcoholic hepatitis. 

Prof Neil Guha, Professor of Hepatology, University of Nottingham, UK

Neil Guha is a Professor of Hepatology at the University of Nottingham. He trained at Guy’s and St. Thomas’s hospitals and began his postgraduate career in hepatology at St. Mary’s Hospital, London. His doctoral thesis, awarded by the University of Southampton, focussed on non-invasive biomarkers of liver fibrosis. He completed his clinical training at the Southampton Liver Unit and was appointed as a clinical lecturer by the University of Southampton in 2008. He moved to Nottingham in 2009 to commence his current post at the National Institute of Health Research Nottingham Biomedical Research Unit/Centre. His research continues to focus on biomarkers of liver fibrosis with current work in serum markers, hypothesis generating technologies, imaging modalities and utilisation of biomarkers in clinical practice including innovative pathways of care. He was a previous NHS Innovation Accelerator Fellow (2015-2018) and is currently (2019 – present) an Associate Senior Tutor at the Centre for Evidence-Based Medicine, University of Oxford. He is the deputy theme lead for GI/Liver within the NIHR Nottingham Biomedical Research Centre.